Gorjan Hrustanovic - 11 Jun 2025 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Reporting relationship: Director
Issuer ticker: OLMA
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 17:00:23 UTC
Prior SEC filing: 20 Jun 2024
Next SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Shane Kovacs, Attorney-in-fact

Key filing fact

Gorjan Hrustanovic filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 13 Jun 2025.

Key facts

This page summarizes Gorjan Hrustanovic's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 17:00.

Change

Previous filing in this sequence was filed on 20 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821194 Primary reporting owner

Hrustanovic Gorjan

Relationship: Director
Address: C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO
Signature: /s/ Shane Kovacs, Attorney-in-fact
Signature date: 13 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OLMA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +24,150
Change %
Price: $0.000000
Shares after: 24,150
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,150
Exercise price: $4.08
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.